AstraZeneca To Revisit Iressa Dosing Following Failed Survival Study
Executive Summary
Inappropriate dose selection is one issue AstraZeneca will examine following Iressa's failure to demonstrate a survival benefit in a Phase IV trial in refractory non-small cell lung cancer, CEO Tom McKillop indicated
You may also be interested in...
Iressa Gets Narrowed Indication Instead Of Withdrawal: New Model For FDA?
FDA's decision to narrow the indication for AstraZeneca's Iressa rather than withdraw the drug could be seen as a model for future products approved under Subpart H that fail in confirmatory trials
Iressa Gets Narrowed Indication Instead Of Withdrawal: New Model For FDA?
FDA's decision to narrow the indication for AstraZeneca's Iressa rather than withdraw the drug could be seen as a model for future products approved under Subpart H that fail in confirmatory trials
Tarceva Pancreatic Cancer Data Do Not Support Broad Use – ASCO Review
Results from Genentech/OSI's Phase III trial of Tarceva (erlotinib) in advanced pancreatic cancer do not support broad use, according to a review at the American Society of Clinical Oncology annual meeting